Phillipson ready to ‘redouble efforts' to cut down on absent pupils
She said progress was beginning to be made, despite government figures which showed the number of children in England who missed at least half of their classes rose to nearly 150,000 in autumn last year.
Writing in The Daily Telegraph, she reiterated that tackling classroom absences was a 'top priority'.
'Reversing the harmful attitudes towards school attendance will not happen overnight. But we are beginning to make progress,' Ms Phillipson wrote.
'Now is the time to redouble our efforts to get more children back through the school gates.
'It's where they learn the habits that will shape them throughout life. It's where the building blocks of a healthy society are laid.'
The Department for Education (DfE) figures, released last week, showed 147,605 pupils were classed as severely absent – which means they missed at least 50% of possible school sessions – in the autumn term of 2024/25. That is compared to 142,487 in the autumn term of 2023/24.
The DfE said research shows a decline in the number of pupils persistently absent 'is likely to improve severe absence' in time.
It added that the rate of increase in severe absence is slowing down compared to the previous two years.
Ms Phillipson said the Government had started to 'turn the tide' with more than five million more days spent in the classroom in the past year.
She said children with special educational needs and disabilities (Send) in particular were missing chunks of time with plans to transform the Send system and expand mental health support in schools.
Among other plans, she highlighted attendance and behaviour hubs being rolled out from September and 'intensive, personalised support' for more than 500 schools facing the biggest challenges.
She called on parents and schools to play their part in ensuring children were spending more time in the classroom.
'We will only continue to drive absence down if we discharge our shared responsibility: parents… sending children to school, schools creating welcoming classrooms, and the Government providing support,' she said.
'That's how we build a brighter future for our children, and for our country too.'
Paul Whiteman, general secretary at school leaders' union NAHT, described last week's attendance figures as 'another small step in the right direction'.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Scientists make concerning discovery about health risks floating in air around us: 'Playing a previously unknown role'
Scientists make concerning discovery about health risks floating in air around us: 'Playing a previously unknown role' Dust particles are not just an annoyance. A new study indicates that "dust particles thrown up from deserts such as the Sahara and Gobi are playing a previously unknown role in air pollution." While aged dust particles from deserts were considered to be too big and dry to have a chemical reaction, they actually facilitate the formation of secondary organic aerosols (SOA). What's happening? Published in National Science Review in a collaborative effort between China, the UK, Japan, and other nations, the study found that "around 50% of water-soluble secondary organic aerosols, primarily considered as SOA, are found in coarse (supermicron) dust particles." This contradicts what scientists previously thought: that secondary organic aerosols are formed in water droplets or fine particles. "This discovery marks a major advance in understanding the chemistry of secondary organic aerosols," co-lead author and University of Birmingham Professor Zongbo Shi said. Shi added, "We've found that water-containing aged dust can act like a sponge and a reactor — absorbing gaseous pollutants and transforming them into particles that affect our health and the climate." Researchers found that aged dust, which had reacted with nitric acid to form calcium nitrate, was able to absorb water even in low humidity — 8% humidity. Then, substances like glyoxal in its gas form can "dissolve, react, and form aqueous-phase secondary organic aerosol." As a statement detailed, "They showed that these dust-driven reactions could account for up to two-thirds of total secondary organic aerosol in some of the world's dustiest regions, from North Africa to East Asia — orders of magnitude more than previous estimates." Why is air pollution concerning? With "air pollution from fine particles linked to millions of premature deaths annually and [contributing] to climate change," as the researchers observed, this discovery will help protect people's health because it will lead to the development of better pollution controls and improve forecasts. Air pollution is also a concern for people who have cardiometabolic disease, as a new study found that they are more at risk for dementia and mild cognitive impairment. Do you worry about companies drilling too deep into the ground? Definitely Depends on what it's for Only if it's near my home Not really Click your choice to see results and speak your mind. What's being done about air pollution? Studies like this are crucial to understanding air pollution and combating the problem. Additional research on the topic is resulting in potential breakthroughs. For example, a Sheffield University study found that mycorrhizal fungi convert air pollution into sugars, which plants intertwined with the fungi then feed on — one possible solution to air pollution. Combating air pollution is complex; that's why it's vital to explore critical climate issues to discover ways to mitigate the problem. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Implantica publishes Interim Report January - June 2025 (Q2)
VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:
Yahoo
an hour ago
- Yahoo
'Having a dog who is clinically obese is a welfare issue' Suffolk vet warns
More than half of the UK's dogs are overweight, which can shorten a pet's life by up to two years, experts have warned. The World Small Animal Veterinary Association describes canine obesity as a "chronic, progressive, and preventable disease." Angela Day, a canine rehabilitation specialist from Bury St Edmunds, said: "Having a dog who is clinically obese is a welfare issue. "Many owners don't realise their dog is overweight until it's already causing harm." Some breeds, such as Labradors, are at higher risk due to genetic factors that make weight control more challenging. Ms Day advised using a body condition score chart to check a dog's shape by feel and sight. Owners should be able to feel their pet's ribs without pressing hard, and see a visible waist from above. She also recommended weighing food portions accurately, cutting out unhealthy treats, and building exercise into a dog's daily routine. Ms Day added: "It's not about depriving your dog. "It's about giving them the best chance of living a long, pain-free, active life."